



## Risankizumab

Revised: November 15, 2023.

CASRN: 1612838-76-2

## Drug Levels and Effects

### Summary of Use during Lactation

No information is available on the clinical use of risankizumab during breastfeeding. Because risankizumab is a large protein molecule with a molecular weight of about 146,000 Da, the amount in milk is likely to be very low. [1] Absorption is unlikely because it is probably destroyed in the infant's gastrointestinal tract.[2] Until more data become available, risankizumab should be used with caution during breastfeeding, especially while nursing a newborn or preterm infant. Waiting for at least 2 weeks postpartum to resume therapy may minimize transfer to the infant.[3]

### Drug Levels

*Maternal Levels.* Relevant published information was not found as of the revision date.

*Infant Levels.* Relevant published information was not found as of the revision date.

### Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

### Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

### Alternate Drugs to Consider

(Psoriasis) Adalimumab, Certolizumab Pegol, Etanercept, Infliximab, Phototherapy, Tretinoin

### References

1. Stratigakis A, Paty D, Zou P, et al. A regression approach for assessing large molecular drug concentration in breast milk. *Reprod Breed* 2023;3:199-207. doi:10.1016/j.repbre.2023.10.003

**Disclaimer:** Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

**Attribution Statement:** LactMed is a registered trademark of the U.S. Department of Health and Human Services.

2. Anderson PO. Monoclonal antibodies during breastfeeding. *Breastfeed Med* 2021;16:591-3. PubMed PMID: 33956488.
3. Krysko KM, Dobson R, Alroughani R, et al. Family planning considerations in people with multiple sclerosis. *Lancet Neurol* 2023;22:350-66. PubMed PMID: 36931808.

## Substance Identification

### Substance Name

Risankizumab

### CAS Registry Number

1612838-76-2

### Drug Class

Breastfeeding

Lactation

Milk, Human

Antibodies, Monoclonal

Anti-Inflammatory Agents

Dermatologic Agents